| Autor: |
De Mattia G; Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. dr.g.demattia@gmail.com., Maffi M; Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy., Mazzantini M; Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. |
| Jazyk: |
angličtina |
| Zdroj: |
Clinical and experimental rheumatology [Clin Exp Rheumatol] 2024 Jul; Vol. 42 (7), pp. 1311-1316. Date of Electronic Publication: 2024 Jul 18. |
| DOI: |
10.55563/clinexprheumatol/7f52vl |
| Abstrakt: |
Osteoporosis is a skeletal disease characterised by reduced bone mass and deterioration of bone microarchitecture, underlying a higher risk of fragility fractures. Several options are available for its treatment, including both anti-resorptive and anabolic agents. The present review discusses and summarises the most recent literature on anabolic treatment, with a focus on abaloparatide, and on the assessment of fragility fracture risk, with a focus on trabecular bone score. Finally, we provide a discussion on the effects of different antiosteoporotic medications in terms of fragility fracture risk reduction. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
